More effective, safer vaccines

Crucell’s patented virosome technology represents a new frontier in vaccinology, simultaneously improving the delivery of specific antigens to target immune cells and bypassing the possible side effects of conventional adjuvanted vaccines. Virosomes stimulate both antibody and cellular immune responses against the antigens they present to the human immune system, ensuring strong protection against disease.

Virosomes are completely biodegradable and virosome-based vaccines do not trigger the adverse reactions that are usually associated with adjuvant (immunity-enhancing) activity. Virosome formulations are compatible with intramuscular, intradermal and intranasal administration and can be used to deliver almost any antigen.

A strong track record

Two marketed Crucell products validate virosome technology: vaccines against hepatitis A and influenza. These vaccines are registered for human use in more than 40 countries and have been administered to more than 30 million individuals. Virosomal vaccines have been shown to elicit highly protective immune responses with excellent safety profiles. The record shows that side effects are much less frequent with virosomal vaccines than with vaccines that contain aluminum as an adjuvant.

Virosomal products from bench to clinic

Crucell has fully operational GMP laboratories dedicated to virosomal products, with integrated upstream and downstream capacities up to several hundreds of thousands of doses. These units are used to develop and produce any new virosomal formulation under strict cGMP conditions.